Upload File

global anticoagulants market outlook to 2020 - demand for patented noacs with prevalence of cardiac...

  • Home
  • Healthcare
  • Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
17

Upload: nitesh-gupta

Post on 12-Apr-2017

18 views

Category:

Healthcare


0 download

Report

TRANSCRIPT

Page 1: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 2: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 3: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 4: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 5: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 6: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 7: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 8: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 9: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 10: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 11: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 12: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 13: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 14: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 15: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 16: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market
Page 17: Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market

NONWARFARIN ORAL ANTICOAGULANTS (NOACS)4 NONWARFARIN ORAL ANTICOAGULANTS (NOACS): THE CLINICAL PHARMACIST’S PERSPECTIVE Atrial Fibrillation AF confers about a 5-fold increased risk

Use of Novel Anticoagulants (NOACs) in Stroke of New Oral Anticoagulants... · • Bleeding and its management • Follow-up . Vitamin K antagonists • Historically the standard

New Oral Anticoagulants (NOACs)prod.qml.com.au/siteassets/qml/newsletter/qml_nl_1_2013_lr.pdfThe advent of the New Oral Anticoagulants (NOACs) promises to provide equivalent benefit

Global Anticoagulants Market: Size, Trends & Forecasts ...daedal-research.com/uploads/images/full/3af6e... · The report entitled “ Global Anticoagulants Market: Size, Trends &

New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Educational

New Oral Anticoagulants (NOACs) - Tallahassee, FL/media/files/heart and vascular/heartsymposium...• Balance risks of bleeding vs risks of clotting – Patients at the highest risk

Dabigatran, rivaroxaban and apixaban, the new oral ... · PDF fileSecond Edition November 2013 Page 1 of 32 Dabigatran, rivaroxaban and apixaban, the new oral anticoagulants (NOACS),

Practical How-to: Treating Patients with New Anticoagulants – case scenarios · 2014-12-23 · Objectives Patient Case #1 o Discuss data using novel oral anticoagulants (NOACs)

NOACs: Innovation in anticoagulation · Anticoagulants (NOACs), and the subsequent National Institute for Health and Care Excellence (NICE) guidance on their use, represents an opportunity

NOACs in Anesthesiology - ZLM · update about NOACs for the perioperative setting. It con-tains an overview of the pharmacological characteristics of the available NOACs and suggestions

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices ... · 32]. NOACs have fewer drug–drug and drug–food inter-actions than warfarin. Although rivaroxaban should be administered

Phase III Trials of New Oral Anticoagulants in the Acute ...€¦ · the NOACs into perspective. This review will compare and contrast the design and results of the Phase III trials

Anticoagulation Protocol - Federal Bureau of Prisons · Federal Bureau of Prisons Anticoagulation Protocol Clinical Guidance March 2018 5 NOVEL ORAL ANTICOAGULANTS (NOACS) Dabigatran,

New Oral Anticoagulants (NOACs) Dabigatran and Rivaroxaban for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation Dr Dipti

Global Anticoagulants Market (2019-2023 Edition)daedal-research.com/uploads/images/full/851dae14c8fe0ec9f2c2fa3… · Anticoagulants which are also known as blood thinners are drugs

NOACs: Innovation in anticoagulation · 2016-09-20 · anticoagulation therapy are not receiving it, suggesting that there is substantial scope to improve the uptake of anticoagulants

‘New’ Anticoagulants Dr Eric Watts...• Six good-quality RCTs compared NOACs • (2 DTI studies, 4 FXainhibitor studies) with warfarin. In AF, NOACs decreased all-cause mortality

313FM.5 DABIGATRAN, RIVAROXABAN, EDOXABAN AND APIXABAN … · anticoagulants (NOACs) are unlike warfarin as they are not vitamin K antagonists and do not require regular INR monitoring

New Oral Anticoagulants - UCSF CME€¦ · New Oral Anticoagulants Management of the Hospitalized Patient San Francisco, CA 2014 Update in Nomenclature NOACs-new oral anticoagulants

Global Anticoagulants Market: Size, Trends & Forecasts (2016-2020) - New Report by Daedal Research

Deciphering the Maze of Evidence from Landmark Trials Evaluating Non-Monitored, Oral Anticoagulants (NOACs) for SPAF New Paradigms in the Science and Medicine

Welcome to CDDW™ 2018! Dr. Roland Valori Making a Difference › images › cddw › cddw2018_finalprogram.pdf · NAFLD non-alcoholic fatty liver disease . NOACS new oral anticoagulants

A Review of the Role of Non-Vitamin K Oral Anticoagulants ... · that evaluated these NOACs, patients received at least 5 days of parenteral anticoagulation with UFH or LMHW prior

The New Oral Anticoagulants (Direct Oral Anticoagulants ......The New Oral Anticoagulants (Direct Oral Anticoagulants - DOACs) Dr Francis Matthey, FRCP, FRCPath Consultant Haematologist

Anticoagulants 1. Parenteral Anticoagulants e.g. heparin 2. Oral anticoagulants e.g. warfarin

Efficacy and safety of dabigatran versus warfarin from the ... · Several non-VKA oral anticoagulants (NOACs) have been developed and tested in randomised clinical trials as alternatives

Open Access Research Evolving landscape of stroke ... · tamin K antagonist oral anticoagulants (Novel Oral ACs (NOACs) such as dabigatran, apixaban and rivaroxaban) was recommended

Antidote for NOACs

Rivaroxaban: An Evaluation of its Cardiovascular Benefit ... · recent years, novel oral anticoagulants (NOACs) that directly target specific components of the coagulation cascade

AHS Powerpoint Template - KTPH - Practical... · 1 Practical Considerations on the Use of Novel Oral Anticoagulants (NOACs) in Stroke Patients with Non-valvular AF AHS-NNI Neuroscience

DIRECT-ACTING ORAL ANTICOAGULANTS (DOACS) · DIRECT-ACTING ORAL ANTICOAGULANTS (DOACS) Antithrombin (anti IIa) • Dabigatran (Pradaxa) Non–vitamin K Oral Anticoagulants (NOACs)

Novel Oral Anticoagulants (NOACs)cshp-ab.ca/_CMS/files/NOAC CSHP Sept 12 2015 Handout FINAL.pdf · Update on Oral Anticoagulants – ... Prosthesis is an artificial device used to

Non-Vitamin K Antagonist Oral Anticoagulants in Patients ... · non–vitamin K antagonist oral anticoagulants (NOACs) with warfarin excluded patients with moderate/severe mitral

Should noacs replace warfarin

ANTICOAGULANTS AND THROMBOLYTIC AGENTS ANTICOAGULANTS AND THROMBOLYTIC AGENTS